Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Using nanopore sequencing in CNS tumour diagnosis and characterization
FY 2020-21
Summary
Every year thousands of people get diagnosed with brain tumour in North America and only about a third of all malignant (type of cancer that can spread to other parts of the body) brain tumour patients survive five years after diagnosis. Fast and accurate diagnosis of brain tumours is extremely crucial to improve patients' survival rate with timely intervention. Current diagnosis methods for brain tumour involves assessment of tissue structure and detection of DNA abnormalities known as markers. Detection protocol for these markers involves multiple testing methods requiring huge infrastructure and long turnaround times further adding to the emotional toll on patients. We want to use a new tool called MinION to overcome these challenges. MinION is a pocket-sized device known to accurately sequence DNA and detect DNA abnormalities in shorter time (hours to days) using relatively simple procedures. We aim to develop and optimize protocols to simultaneously detect the most common markers of brain tumours on a single MinION device to diagnose and characterize types of brain tumour. One of the markers we want to detect is methylation status on a gene called MGMT. Patients with methylated MGMT react better to chemotherapy and have greater survival rate. By assessing methylation status of MGMT in brain tumour patients, physicians can provide personalized treatments. We will be using brain tumour samples from patients with known tumour type and DNA abnormalities to detect the markers using MinION. We will assess validity of our developed testing methods by comparing our results with the known marker statuses of the tumour samples. In the future, this tool can also be implemented in diagnosing other types of tumours to acquire faster and easier results.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
449532
Name
Mimosa Mashiat L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Using nanopore sequencing in CNS tumour diagnosis and characterization
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
1p/19q Codeletion; Brain Tumour; Dna Sequencing; Glioblastoma; Idh Mutation; Methylation; Mgmt Promoter; Minion; Molecular Biomarkers; Nanopore Sequencing
Abstract
Every year thousands of people get diagnosed with brain tumour in North America and only about a third of all malignant (type of cancer that can spread to other parts of the body) brain tumour patients survive five years after diagnosis. Fast and accurate diagnosis of brain tumours is extremely crucial to improve patients' survival rate with timely intervention. Current diagnosis methods for brain tumour involves assessment of tissue structure and detection of DNA abnormalities known as markers. Detection protocol for these markers involves multiple testing methods requiring huge infrastructure and long turnaround times further adding to the emotional toll on patients. We want to use a new tool called MinION to overcome these challenges. MinION is a pocket-sized device known to accurately sequence DNA and detect DNA abnormalities in shorter time (hours to days) using relatively simple procedures. We aim to develop and optimize protocols to simultaneously detect the most common markers of brain tumours on a single MinION device to diagnose and characterize types of brain tumour. One of the markers we want to detect is methylation status on a gene called MGMT. Patients with methylated MGMT react better to chemotherapy and have greater survival rate. By assessing methylation status of MGMT in brain tumour patients, physicians can provide personalized treatments. We will be using brain tumour samples from patients with known tumour type and DNA abnormalities to detect the markers using MinION. We will assess validity of our developed testing methods by comparing our results with the known marker statuses of the tumour samples. In the future, this tool can also be implemented in diagnosing other types of tumours to acquire faster and easier results.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mimosa, Mashiat L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~